Jason Shafrin, PhD

Jason Shafrin, PhD, FTI Consulting
Guest Blog
Has Medicine Reached the Digital Age? Five Key Obstacles Digital Technologies Still Need to Overcome
08/26/2021
Jason Shafrin, PhD, and David Gruber, MD, MBA, discuss challenges digital health innovators face and what digital health technologies must provide to be successful.
Jason Shafrin, PhD, and David Gruber, MD, MBA, discuss challenges digital health innovators face and what digital health technologies must provide to be successful.
Jason Shafrin, PhD, and David...
08/26/2021
Journal of Clinical Pathways
Pharma Insights
Open-Source Tools for Value Assessment: A Promising Approach
06/14/2018
While many advancements have been made thus far in the progression toward value-based health care, there are persistent challenges in the measurement of value. In order to deliver value-based care, health care...
While many advancements have been made thus far in the progression toward value-based health care, there are persistent challenges in the measurement of value. In order to deliver value-based care, health care...
While...
06/14/2018
Journal of Clinical Pathways
Healthcare Economist
Why Don’t Physicians Follow Evidence-Based Guidelines More Often?
09/19/2019
Jason Shafrin, PhD, explains the numerous barriers for physicians to follow evidence-based guidelines and asserts that there will never come a time when 100% of practiced medicine will be fully evidence-based.
Jason Shafrin, PhD, explains the numerous barriers for physicians to follow evidence-based guidelines and asserts that there will never come a time when 100% of practiced medicine will be fully evidence-based.
Jason Shafrin, PhD, explains the...
09/19/2019
Journal of Clinical Pathways
Shafrin
Healthcare Economist
Which Strategies Are Payers and Employers Using to Cover Ophan Drugs?
06/20/2021
Jason Shafrin, PhD, discusses a survey which explored affordability challenges posed by orphan drugs from the payer, provider, and employer perspectives.
Jason Shafrin, PhD, discusses a survey which explored affordability challenges posed by orphan drugs from the payer, provider, and employer perspectives.
Jason Shafrin, PhD, discusses a...
06/20/2021
Journal of Clinical Pathways
Pharma Insights
Does COVID-19 Threaten the Progress Pharmaceuticals Have Made in Reducing Cancer Mortality Over the Last 20 Years?
12/16/2020
The development and introduction of new pharmaceuticals has played a pivotal role in reducing US cancer deaths. While pharmaceuticals have played a significant role in reducing cancer mortality, winning the war on...
The development and introduction of new pharmaceuticals has played a pivotal role in reducing US cancer deaths. While pharmaceuticals have played a significant role in reducing cancer mortality, winning the war on...
The...
12/16/2020
Journal of Clinical Pathways
Healthcare Economist
Why Use Real-World Evidence for Clinical Trials?
09/28/2019
Jason Shafrin, PhD, asserts that, in some cases, RWE may be a viable alternative to the standard randomized controlled trials currently required for FDA drug approval.
Jason Shafrin, PhD, asserts that, in some cases, RWE may be a viable alternative to the standard randomized controlled trials currently required for FDA drug approval.
Jason Shafrin, PhD, asserts...
09/28/2019
Journal of Clinical Pathways
Jason Shafrin, PhD
Healthcare Economist
Impact of Biosimilar Entry on Drug Costs
12/20/2021
Jason Shafrin, PhD, discusses a paper examining how prices vary for branded, physician-administered drugs which had generic or biosimilar versions introduced before 2005.
Jason Shafrin, PhD, discusses a paper examining how prices vary for branded, physician-administered drugs which had generic or biosimilar versions introduced before 2005.
Jason Shafrin, PhD, discusses a...
12/20/2021
Journal of Clinical Pathways
Pharma Insights
The Clash: Treatment Advances and Value Measurements in Oncology
04/11/2017
Cancer has or will affect nearly every person at some point in their lives, either directly or indirectly. The fight against cancer is central to society; in recent years, treatment advances and prevention strategies...
Cancer has or will affect nearly every person at some point in their lives, either directly or indirectly. The fight against cancer is central to society; in recent years, treatment advances and prevention strategies...
Cancer...
04/11/2017
Journal of Clinical Pathways
Healthcare Economist
How to Value Curative Therapies
10/08/2019
Jason Shafrin, PhD, provides a description of the tools being created by health economists to quantify additional value components of transformative, curative treatments.
Jason Shafrin, PhD, provides a description of the tools being created by health economists to quantify additional value components of transformative, curative treatments.
Jason Shafrin, PhD, provides a...
10/08/2019
Journal of Clinical Pathways
Shafrin
Healthcare Economist
Alternative Payment Models: Where Are We Now?
02/07/2022
Jason Shafrin, PhD, discusses a report from the Health Care Payment Learning and Action Network which assessed whether alternative payment models have gained market share from 2019 to 2020.
Jason Shafrin, PhD, discusses a report from the Health Care Payment Learning and Action Network which assessed whether alternative payment models have gained market share from 2019 to 2020.
Jason Shafrin, PhD, discusses a...
02/07/2022
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use